Via Completes Enrollment in Acute Coronary Syndrome Study
Posted on: Friday, 16 May 2008, 09:00 CDT
Via Pharmaceuticals has completed patient enrollment in its acute coronary syndrome study, which is one of three Phase II trials investigating VIA-2291, the company's lead product candidate in cardiovascular disease.
The acute coronary syndrome (ACS study), which enrolled 191 patients, is designed to establish dose and safety data in patients with ACS who have experienced a recent heart attack or unstable angina. The study includes measures of leukotrienes, biomarkers of inflammation, as well as medical imaging of the coronary vessels to evaluate the impact on plaque characteristics in a subset of patients. Patients in the study are treated once daily with one of three dose levels of VIA-2291 or placebo.
This is the second Phase II study of VIA-2291 to complete enrollment. In March 2008, Via announced completion of enrollment in its carotid endarterectomy (CEA) trial, which is designed to provide direct evaluation of VIA-2291's effect on inflammation by analyzing plaque removed from the carotid arteries in patients treated with VIA-2291 or placebo. Enrollment in the third Phase II clinical trial, the FDG-PET Trial, is ongoing.
VIA-2291 is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed as a once-daily, oral drug to potentially decrease the risk of major adverse cardiac events associated with inflammation, including heart attack and stroke.
Via expects to report top line results from the ACS trial soon after top line CEA study results are presented in the third quarter of 2008.
Source: Datamonitor
Related Articles
- Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
- Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
- Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease
- CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial
- Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
- Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 2 PROPEL Trial of PDX in Patients With Peripheral T-Cell Lymphoma
- Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
- Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Study of EFAPROXYN(TM) in Women With Brain Metastases Originating From Breast Cancer
- The Medicines Company Commences Patient Enrollment in Pivotal Phase III Clinical Trial of Cangrelor
- Medivation Exceeds Patient Enrollment Target in Phase 2 Alzheimer's Disease Trial
 |
 |
User Comments (0)
RSS Feeds